Back
Intra-Cellular Therapies Stock Predictions
Sell
37
ITCI
Intra-Cellular Therapies
Last Price:
65.29
Seasonality Move:
-0.94%
7 Day Trial
ALL ACCESS PASS
$
7
Intra-Cellular Therapies Stock Forecast
- Over the next 52 weeks, Intra-Cellular Therapies has on average historically risen by 28.3% based on the past 10 years of stock performance.
- Intra-Cellular Therapies has risen higher in 8 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 80%
-
Is Intra-Cellular Therapies Stock Undervalued?
The current Intra-Cellular Therapies [ITCI] share price is $65.00. The Score for ITCI is 37, which is 26% below its historic median score of 50, and infers higher risk than normal. - ITCI is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
Will Intra-Cellular Therapies Stock Go Up Next Year?
- Over the next 52 weeks, Intra-Cellular Therapies has on average historically risen by 28.3% based on the past 10 years of stock performance.
Intra-Cellular Therapies Stock Rating
Sell
37
Intra-Cellular Therapies (ITCI)
is a Sell
Is Intra-Cellular Therapies overpriced?
- Intra-Cellular Therapies has risen higher in 8 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 80%
Intra-Cellular Therapies Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Pharmaceuticals
Sector:
Health Care
Type:
stock
Website:
intracellulartherapies.com
52-Week Data
52-Week High:
84.89
52-Week Low:
45.50
Prediction Charts
Market Cap:
6.86B
Price in USD:
65.00
Volume:
767.79K
Beta:
1.10
Technical Analysis
SMA50:
68.71
SMA100:
69.15
SMA200:
62.77
52-Wk Change:
2.51%
Stock Predictions
-
Is Intra-Cellular Therapies stock public?
Yes, Intra-Cellular Therapies is a publicly traded company. -
What is the Intra-Cellular Therapies stock quote today?
The Intra-Cellular Therapies stock price is 65.00 USD today. -
How to buy Intra-Cellular Therapies stock online?
You can buy Intra-Cellular Therapies shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
Date | Opening | Closing | Minimum | Maximum |
---|---|---|---|---|
Apr-30 | 72.45 | 71.80 | 72.83 | 71.38 |
May-1 | 71.61 | 72.67 | 73.68 | 71.61 |
May-2 | 73.77 | 70.34 | 73.77 | 69.98 |
May-3 | 71.07 | 68.80 | 71.35 | 68.48 |
May-6 | 68.88 | 70.96 | 71.02 | 68.26 |
May-7 | 69.72 | 71.21 | 71.64 | 68.61 |
May-8 | 71.12 | 67.00 | 71.22 | 66.95 |
May-9 | 66.97 | 65.53 | 67.23 | 65.45 |
May-10 | 65.75 | 64.96 | 66.71 | 64.92 |
May-13 | 65.16 | 66.32 | 67.22 | 65.16 |
May-14 | 66.76 | 65.71 | 67.27 | 65.17 |
May-15 | 66.68 | 66.84 | 68.16 | 66.51 |
May-16 | 66.72 | 66.53 | 67.10 | 65.51 |
May-17 | 66.88 | 65.00 | 66.88 | 64.92 |
Intra-Cellular Therapies Earnings
Intra-Cellular Therapies Earnings Report: Per Share Intra-Cellular Therapies Earnings Q1 Q2 Q3 and Q4 last year and next year.
Intra-Cellular Therapies Forecast Revenue Growth
Intra-Cellular Therapies Stock Analysis: Historical quarterly revenues per share for Intra-Cellular Therapies and historical quarterly revenue growth:
- Analysts estimate an earnings increase this quarter of $0.45 per share, a decrease next quarter of $0.02 per share, an increase this year of $1.08 per share, and an increase next year of $1.44 per share.
* Intra-Cellular Therapies stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.